Literature DB >> 10655475

Rational discovery of novel nuclear hormone receptor antagonists.

M Schapira1, B M Raaka, H H Samuels, R Abagyan.   

Abstract

Nuclear hormone receptors (NRs) are potential targets for therapeutic approaches to many clinical conditions, including cancer, diabetes, and neurological diseases. The crystal structure of the ligand binding domain of agonist-bound NRs enables the design of compounds with agonist activity. However, with the exception of the human estrogen receptor-alpha, the lack of antagonist-bound "inactive" receptor structures hinders the rational design of receptor antagonists. In this study, we present a strategy for designing such antagonists. We constructed a model of the inactive conformation of human retinoic acid receptor-alpha by using information derived from antagonist-bound estrogen receptor-alpha and applied a computer-based virtual screening algorithm to identify retinoic acid receptor antagonists. Thus, the currently available crystal structures of NRs may be used for the rational design of antagonists, which could lead to the development of novel drugs for a variety of diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655475      PMCID: PMC15503          DOI: 10.1073/pnas.97.3.1008

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.

Authors:  P Fitzgerald; M Teng; R A Chandraratna; R A Heyman; E A Allegretto
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

Review 2.  RU486 (mifepristone): mechanisms of action and clinical uses.

Authors:  F Cadepond; A Ulmann; E E Baulieu
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

3.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Authors:  J P Renaud; N Rochel; M Ruff; V Vivat; P Chambon; H Gronemeyer; D Moras
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

4.  Identification of a retinoic acid receptor alpha subtype specific agonist.

Authors:  M Teng; T T Duong; E S Klein; M E Pino; R A Chandraratna
Journal:  J Med Chem       Date:  1996-08-02       Impact factor: 7.446

5.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

6.  Molecular docking programs successfully predict the binding of a beta-lactamase inhibitory protein to TEM-1 beta-lactamase.

Authors:  N C Strynadka; M Eisenstein; E Katchalski-Katzir; B K Shoichet; I D Kuntz; R Abagyan; M Totrov; J Janin; J Cherfils; F Zimmerman; A Olson; B Duncan; M Rao; R Jackson; M Sternberg; M N James
Journal:  Nat Struct Biol       Date:  1996-03

7.  Detailed ab initio prediction of lysozyme-antibody complex with 1.6 A accuracy.

Authors:  M Totrov; R Abagyan
Journal:  Nat Struct Biol       Date:  1994-04

8.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.

Authors:  R Mukherjee; P J Davies; D L Crombie; E D Bischoff; R M Cesario; L Jow; L G Hamann; M F Boehm; C E Mondon; A M Nadzan; J R Paterniti; R A Heyman
Journal:  Nature       Date:  1997-03-27       Impact factor: 49.962

9.  Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells.

Authors:  G Giannini; M I Dawson; X Zhang; C J Thiele
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

10.  Dopamine neuron agenesis in Nurr1-deficient mice.

Authors:  R H Zetterström; L Solomin; L Jansson; B J Hoffer; L Olson; T Perlmann
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

View more
  26 in total

1.  Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles.

Authors:  So-Jung Park; Irina Kufareva; Ruben Abagyan
Journal:  J Comput Aided Mol Des       Date:  2010-05-09       Impact factor: 3.686

2.  Kinetic analysis of estrogen receptor/ligand interactions.

Authors:  Rebecca L Rich; Lise R Hoth; Kieran F Geoghegan; Thomas A Brown; Peter K LeMotte; Samuel P Simons; Preston Hensley; David G Myszka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

3.  Making virtual screening a reality.

Authors:  John T Koh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

4.  A validation study on the practical use of automated de novo design.

Authors:  Martin Stahl; Nikolay P Todorov; Tim James; Harald Mauser; Hans-Joachim Boehm; Philip M Dean
Journal:  J Comput Aided Mol Des       Date:  2002-07       Impact factor: 3.686

5.  Structural determinants of PERK inhibitor potency and selectivity.

Authors:  Hong Wang; Jaime Blais; David Ron; Timothy Cardozo
Journal:  Chem Biol Drug Des       Date:  2010-12       Impact factor: 2.817

6.  Metformin interacts with AMPK through binding to γ subunit.

Authors:  Yaya Zhang; Yongjun Wang; Chuanen Bao; Yingyi Xu; Huili Shen; Junjie Chen; Jianghua Yan; Yuqiang Chen
Journal:  Mol Cell Biochem       Date:  2012-05-30       Impact factor: 3.396

7.  Design of ligand binding to an engineered protein cavity using virtual screening and thermal up-shift evaluation.

Authors:  Claudia Machicado; Jon López-Llano; Santiago Cuesta-López; Marta Bueno; Javier Sancho
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

Review 8.  Orphan nuclear receptors in drug discovery.

Authors:  Yanhong Shi
Journal:  Drug Discov Today       Date:  2007-04-26       Impact factor: 7.851

9.  A Discovery Funnel for Nucleic Acid Binding Drug Candidates.

Authors:  Patrick A Holt; Robert Buscaglia; John O Trent; Jonathan B Chaires
Journal:  Drug Dev Res       Date:  2011-03-01       Impact factor: 4.360

10.  Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking.

Authors:  Matthieu Schapira; Bruce M Raaka; Sharmistha Das; Li Fan; Maxim Totrov; Zhiguo Zhou; Stephen R Wilson; Ruben Abagyan; Herbert H Samuels
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.